Fig. 1: The potential post-translational modification of SGK196 may involve in the development of BLBC.
From: N-glycosylated SGK196 suppresses the metastasis of basal-like breast cancer cells
a GEPIA database shows the mRNA level of SGK196 in BC tissue and in normal breast tissues (num (T) = 1085; num (N) = 291). b Representative images of SGK196 expression in tissue microarray chip. c Scatter plots depicting the expression of SGK196 in BC tissues (n = 63) and normal adjacent breast tissues (n = 8). d, e RFS curves were plotted for all BC patients (d) and RFS curves were plotted for basal-like type patients (e). Data was analyzed using Kaplan-Meier Plotter. Patients with high expression are indicated in red line, and patients with low expression in black line. HR means hazard ratio. The P-value was calculated by a log-rank test. f Immunoblotting analysis of SGK196 expression in different subtypes BC cell lines. g Immunoblotting analysis of SGK196 expression in 3 pairs of BC tissues and adjacent normal tissues. (N: adjacent normal breast tissues; T: BC tissues; case1 and case 2 belong to luminal type, while case 3 belongs to basal-like type).
